1-year overall survival when adding bevacizumab to standard chemotherapy. 8 Moreover, the ECOG trial failed to demonstrate a survival advantage for bevacizumab-carboplatin-paclitaxel over carboplatin-paclitaxel (HR, 0.89; 95% CI, 0.70-1.14) among the subgroup of 366 trial participants aged 65 years or older. 6 An unplanned subset analysis in 224 patients aged 70 years or older at diagnosis from the same trial also suggested no significant differences in overall survival (11.3 vs 12.1 months) between bevacizumab-carboplatinpaclitaxel and carboplatin-paclitaxel. 9 Notwithstanding the uncertainty about benefits in the population aged 65 years or older, the Centers for Medicare & Medicaid Services (CMS) has covered bevacizumab therapy for its enrollees subsequent to FDA approval. 10 Little is known about how clinicians have interpreted efficacy studies to formulate treatment recommendations, and given that approximately two-thirds of patients with lung cancer receive their diagnoses at age 65 years or older, 4 establishing the survival advantage of bevacizumab in the Medicare population is a priority for informed decision making.
Using analytic strategies to address confounding and selection bias caused by the lack of treatment randomization in observational studies that may limit ability to make valid inferences about causality, we examined whether adding bevacizumab to first-line carboplatin-paclitaxel was associated with improved survival in the Medicare population with advanced non−squamous cell NSCLC.
METHODS

Data Source
We used population-based data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program linked to Medicare claims. The SEER database covers 17 cancer registries and captures cancer incidence for approximately 28% of the US population.
11 SEER includes information on cancer site, histology, stage, grade, and dates of diagnosis and death, as well as patient demographic characteristics. 12, 13 Medicare Parts A and B claims contain extensive service-level data for hospital inpatient and outpatient, skilled nursing facility, home health agency, and hospice care, as well as physician services and durable medical equipment. 12 SEER data for patients with diagnoses from January 1, 2002, through December 31, 2007 , were matched to Medicare claims data from January 1, 2001, through December 31, 2009 . The study was approved by the institutional review board at the Dana-Farber Harvard Cancer Center.
Study Participants
The study cohort included patients aged 65 years or older with pathologically confirmed stage IIIB or IV non−squamous cell NSCLC diagnosed between 2002 and 2007 who received first-line chemotherapy with bevacizumabcarboplatin-paclitaxel or carboplatinpaclitaxel within 4 months of diagnosis. Patients were excluded if they had other primary cancers diagnosed either before or after NSCLC or died within 30 days of NSCLC diagnosis. To ensure completeness of Medicare claims information, patients who were not continuously eligible for Medicare Parts A and B or who were enrolled in a health maintenance organization at any point from diagnosis to death or 6-month follow-up were also excluded. Staging information was available in SEER and defined according to the American Joint Committee on Cancer (AJCC) staging manual, 6th edition. 14 The goal of this analysis was to compare survival outcomes for elderly patients with advanced NSCLC who received first-line carboplatin and paclitaxel alone with those who also received bevacizumab. Thus, our primary comparison groups were patients with diagnoses in 2006 Medicare claims have been shown to have high sensitivity and specificity for identification of chemotherapy agents among elderly patients with lung cancer. 15, 16 First-line chemotherapy was defined as chemotherapy administered within 4 months after the NSCLC diagnosis. Specific agents were identified from Medicare outpatient, physician, or durable medical equipment claims by using Healthcare Common Procedure Coding System codes and National Drug Codes. The date of the first chemotherapy claim was considered the start date of chemotherapy. Additional agents received within 8 days of the first drug were considered components of the same regimen. Any patients whose initial chemotherapy was delivered concurrently with radiotherapy, defined as start dates within 8 days of each other, were excluded.
Survival Outcomes
The primary outcome was all-cause mortality, defined as the number of survival months from the administration of first chemotherapy agent until the date of death or the end of the obser-vation period. Date of death was reported in Medicare enrollment files capturing death through December 31, 2009 . Patients alive at the end of follow-up were censored.
Baseline Characteristics
Demographic and clinical data obtained from SEER included age, sex, race/ethnicity, marital status, geographic region, urban residency, ecological surrogates for educational attainment and median income, comorbidity, AJCC stage, and tumor grade according to the categories shown in TABLE 1. Race/ethnicity was classified as nonHispanic white, non-Hispanic black, and other (eg, Hispanic, Asian/Pacific Islander, American Indian/Alaska Native). Race in SEER is identified from patients' medical records and registration information, and Hispanic ethnicity in SEER is determined through a Hispanic surname algorithm that has better sensitivity than that recorded in Medicare data. 21 To measure the burden of comorbidities, we applied the Deyo adaptation 17 of the Charlson comorbidity index, 18 modified to exclude cancer diagnoses, to Medicare inpatient, outpatient, and physician claims during the 12-month period extending from 13 months to 1 month before NSCLC diagnosis using lung cancerspecific weights as described by Klabunde et al. 19, 20 We then categorized the comorbidity score into 3 groups (0, 1, and Ն2).
Statistical Analysis
Differences in distribution of baseline characteristics between the bevacizumab-treated group and each of the carboplatin-paclitaxel control groups were evaluated using the 2 test. The Kaplan-Meier survival method was used to estimate median survival and we tested for crude differences among the 3 groups using a log-rank test. We conducted unadjusted and multivariable Cox proportional hazards models controlling for all demographic and clinical characteristics listed in Table 1 to examine whether the addition of bevacizumab to carboplatin and paclitaxel 18 modified to exclude cancer diagnoses, to Medicare inpatient, outpatient, and physician claims during the 12-month period extending from 13 months to 1 month before NSCLC diagnosis using lung cancer-specific weights as described by Klabunde et al. 19, 20 improved overall survival in patients with advanced non−squamous cell NSCLC. We compared the bevacizumab-treated group with both carboplatin-paclitaxel cohorts.
We used propensity score analyses 22 to balance measurable confounders between the group receiving bevacizumab and each of the 2 carboplatinpaclitaxel groups. Multivariable logistic regression was used to predict treatment (bevacizumab-carboplatinpaclitaxel compared with carboplatinpaclitaxel) based on confounding covariates, including age, sex, race/ ethnicity, marital status, geographic region, urban residency, tumor grading, Census tract education, median income, modified Charlson comorbidities, and AJCC stage. Each patient was then assigned an estimated propensity score, which was his/her predicted probability of receiving bevacizumab on the basis of his/her observed baseline characteristics. 23, 24 The cohort was then divided into 5 strata defined by quintiles of estimated propensity scores. 25 Next, we used P values of the 2 test to assess whether patients' baseline characteristics were balanced across the 2 treatment groups within each stratum. Finally, Cox proportional hazards models were conducted separately within each stratum to compare overall survival of patients receiving vs not receiving bevacizumab, and then the 5 HRs estimated from each stratum were combined into an overall HR for the whole cohort. 26 Cox models were also performed by applying propensity scores to adjust for group differences in 3 alternative ways: (1) regression adjustment (ie, inclusion of the propensity score as a linear predictor in the model); (2) propensity score matching, which paired bevacizumabcarboplatin-paclitaxel and carboplatinpaclitaxel patients who were similar in terms of their measurable characteristics; and (3) use of the propensity score to create stabilized weights, defined as the inverse probability of treatment weighting. 27, 28 The analyses were first performed on the bevacizumab combination and carboplatin-paclitaxel 2006-2007 cohorts, then repeated on the bevacizumab combination and carboplatin-paclitaxel 2002-2005 groups.
We also performed subgroup analyses for 2 characteristics that were imbalanced between treatment groups; specifically, stage IV disease, which was more prevalent in the bevacizumab group, and comorbidity, which was less prevalent in the bevacizumab group. Sensitivity analyses evaluated the potential impact of immortal time bias 29 and alternative strategies for treatment assignment on results. Specifically, we measured survival starting from carboplatin-paclitaxel treatment day 9, the end of the 8-day interval used to ascertain concurrent bevacizumab therapy, instead of from carboplatinpaclitaxel treatment day 1, and we expanded the interval used to identify bevacizumab concurrent administration with carboplatin-paclitaxel from 8 to 30 days, while initiating measurement of survival at day 31. SAS software, version 9.2 (SAS Institute Inc) was used for all analyses. Statistical significance was set at PϽ.05 and all tests were 2-tailed.
RESULTS
Cohort Description and Baseline Characteristics
From an initial sample of 59 770 pa- Table 1 and were similar in most respects. Bevacizumabtreated patients were less likely to have 2 or more comorbidities (6.3% vs 16.3%; P Ͻ .001) and more likely to None of the 4 propensity scoreadjusted models demonstrated any evidence to support the superiority of bevacizumab-carboplatin-paclitaxel to carboplatin-paclitaxel. For example, Table 2) . Neither subgroup nor sensitivity analyses changed our essential finding that bevacizumab was not associated with a survival advantage. Table 2 ). To contextualize these findings, we also evaluated the association between other measured characteristics and overall survival comparing both the bevacizumab and carboplatin-paclitaxel 2006-2007 groups and the bevacizumab and carboplatin-paclitaxel 2002-2005 groups and found that later-stage disease (stage IV vs IIIB) and higher burden of comorbidity were associated with inferior survival (TABLE 3) .
COMMENT
Using data from SEER-Medicare, we compared survival outcomes for patients with advanced NSCLC of nonsquamous cell subtype who were treated with carboplatin and paclitaxel, the prevailing standard chemotherapy regimen, with or without bevacizumab. We found that in the wake of the 2006 FDA approval decision, adoption of bevacizumab was by no means universal. For patients with diagnoses in 2006 and 2007, only 20% and 22%, respectively, received bevacizumab as a component of their firstline carboplatin-paclitaxel chemotherapy regimen. In addition, we found no evidence that bevacizumab conferred a survival advantage for recipients in multivariable models that controlled for observable demographic and clinical patient attributes.
Our pattern-of-care findings in the Medicare population suggest that the medical oncology community requires therapeutic evidence specific to a particular disease prior to adoption. Medical oncologists, particularly those in private practice, may have financial incentives to administer new, expensive treatment agents if they can purchase them for less money than the CMS reimburses. Because bevacizumab is expensive [30] [31] [32] and was covered by the CMS, if oncologists were subject to powerful treatment incentives as some have suggested, 33 we would have expected to observe them in this context. That we did not observe rapid or complete uptake of bevacizumab provides some measure of reassurance that oncologists are circumspect and judicious in their use of new agents with uncertain benefit in the Medicare population.
The magnitude of the survival benefit we describe is lower than that observed in clinical trial participants. In our study, the median survival for patients treated with the bevacizumab combination was 9.7 months vs 12.3 months for participants in the ECOG 4599 trial. The carboplatin-paclitaxel patients in our study had median survival of 8. 18 modified to exclude cancer diagnoses, to Medicare inpatient, outpatient, and physician claims during the 12-month period extending from 13 months to 1 month before NSCLC diagnosis using lung cancer-specific weights as described by Klabunde et al. 19, 20 platin-paclitaxel and 42% of bevacizumab-carboplatin-paclitaxel trial participants were aged 65 years or older at diagnosis, 6 whereas in our Medicare cohort, 100% were aged 65 years or older and, indeed, more than onethird were older than 75 years at diagnosis. The marginally lower median survival rates in our observational cohort compared with either the complete group or elderly subgroup of the efficacy cohort may also be attributed to differences in clinical factors such as performance status and baseline lung function that cannot be ascertained from SEER-Medicare data.
Researchers have called for prospective trials specifically designed for elderly patients to better define the role of intensive cancer treatments that are routinely demonstrated to have superiority in clinical trials that recruit patients who are younger and/or healthier than the general population of patients with the index malignancy. [34] [35] [36] However, elderly-specific trials with bevacizumab face practical barriers. For example, Merza et al 37 studied 106 elderly male patients diagnosed as having advanced NSCLC at a Veterans Administration medical center and found that only 10% of patients were candidates for bevacizumab after applying exclusion criteria used in ECOG 4599 and another bevacizumab combination trial. Our study supplements the nonsignificant results from the subset analyses of older patients in ECOG 4599 6, 9 and substantiates prevailing practice patterns that demonstrate that oncologists are circumspect about using bevacizumab for their elderly patients with NSCLC.
Our study must be interpreted in the context of limitations inherent to all observational studies as well as those that rely on administrative data sources such as Medicare. First, the study was limited to Medicare fee-for-service beneficiaries who were aged 65 years or older and living in a SEER region at diagnosis. This cohort may not be representative of all patients with non−squamous cell NSCLC in the United States, 12 although it is likely to be more representative than the sample of clinical trial participants. Second, SEER-Medicare lacks essential clinical details, such as the presence of molecular biomarkers, performance status, and baseline pulmonary function, which may be associated with the selection of chemotherapy agents, survival, or both. However, the inability to identify patients with poor baseline lung function and limited performance status or other clinical contraindications to bevacizumab such as significant hemoptysis and brain metastases would be expected to widen rather than narrow the apparent gap in survival between patients receiving bevacizumab-carboplatin-paclitaxel vs carboplatin-paclitaxel. In an observational cohort, patients with relative contraindications to bevacizumab are more likely to be included in the carboplatinpaclitaxel cohort, and this should increase the survival advantage of bevacizumab-carboplatin-paclitaxel relative to carboplatin-paclitaxel. That we did not observe this lends credence to our finding that there is no sizeable benefit from adding bevacizumab to carboplatin-paclitaxel in the Medicare population. Third, because we have NSCLC diagnoses only through 2007, the sample size for bevacizumab-carboplatinpaclitaxel-treated patients was small, and we cannot exclude the possibility that more recent data and/or a larger sample would yield different results. Fourth, differences in second-and thirdline chemotherapy between study groups may have contributed to survival outcomes; the overall survival might favor the group that had a higher percentage of patients receiving further lines of chemotherapy. Finally, although we used statistical techniques to mitigate the potential for imbalance between our cohorts based on measured prognostic factors, the potential for selection bias based on unmeasured factors that predisposed patients to be included in a particular treatment group cannot be excluded.
In conclusion, our analyses suggest that the addition of bevacizumab to carboplatin and paclitaxel is not associated with demonstrable improvement in overall survival in the Medicare population. In the future, for malignancies like NSCLC that disproportionately affect elderly patients or where the CMS covers a large proportion of treatment costs, negotiations with pharmaceutical sponsors of pivotal trials might mandate adequate representation of elderly patients and/or preplanned subgroup analyses relevant to the Medicare population. Absent this information, clinicians will need to rely on efficacy data from subgroup analysis randomized trials, observational data such as this report, and their clinical judgment to make treatment recommendations. Given that neither subgroup analyses from efficacy studies nor observational data analyses identify a benefit for adding bevacizumab to standard carboplatin-paclitaxel therapy, bevacizumab should not be considered standard of care in this context. Clinicians should exercise caution in making treatment recommendations and should use bevacizumab judiciously for their older patients.
